FORTIFI-HN01 Trial Enrolls First Patients for Novel HNSCC Therapy
The FORTIFI-HN01 trial has begun enrolling patients with advanced head and neck cancer to evaluate ficerafusp alfa plus pembrolizumab as a first-line therapy.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
CAR T-Cells Demonstrate Efficacy, Tolerability in Early-Relapsed DLBCL
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first article of a 2-part series.
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
CRISTALLO Study of Venetoclax/Obinutuzumab Achieves Superior MRD in CLL
The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline chronic lymphocytic leukemia therapy.
Casdatifan Shows Promise in Treating Clear Cell Renal Cell Carcinoma
Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.
